| Practical methods for incorporating summary time-to-event data into meta-analysis JF Tierney, LA Stewart, D Ghersi, S Burdett, MR Sydes Trials 8, 1-16, 2007 | 5399 | 2007 |
| Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... The Lancet 387 (10024), 1163-1177, 2016 | 2112 | 2016 |
| Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial A Cuschieri, S Weeden, J Fielding, J Bancewicz, J Craven, V Joypaul, ... British journal of cancer 79 (9), 1522-1530, 1999 | 1812 | 1999 |
| Abiraterone for prostate cancer not previously treated with hormone therapy ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ... New England Journal of Medicine 377 (4), 338-351, 2017 | 1792 | 2017 |
| Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study GC Barnett, CE Coles, RM Elliott, C Baynes, C Luccarini, D Conroy, ... The lancet oncology 13 (1), 65-77, 2012 | 1759 | 2012 |
| Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ... The Lancet 392 (10162), 2353-2366, 2018 | 1104 | 2018 |
| Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial DP Dearnaley, MR Sydes, JD Graham, EG Aird, D Bottomley, RA Cowan, ... The lancet oncology 8 (6), 475-487, 2007 | 1077 | 2007 |
| Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial P Warde, M Mason, K Ding, P Kirkbride, M Brundage, R Cowan, ... The Lancet 378 (9809), 2104-2111, 2011 | 689 | 2011 |
| High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial HC Schouten, W Qian, S Kvaloy, A Porcellini, H Hagberg, HE Johnsen, ... Journal of clinical oncology 21 (21), 3918-3927, 2003 | 636 | 2003 |
| Adaptive designs in clinical trials: why use them, and how to run and report them P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ... BMC medicine 16, 1-15, 2018 | 604 | 2018 |
| Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial DP Dearnaley, G Jovic, I Syndikus, V Khoo, RA Cowan, JD Graham, ... The lancet oncology 15 (4), 464-473, 2014 | 536 | 2014 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 523 | 2018 |
| Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019) ND James, MR Spears, NW Clarke, DP Dearnaley, JS De Bono, J Gale, ... European urology 67 (6), 1028-1038, 2015 | 520 | 2015 |
| Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label … NM Marina, S Smeland, SS Bielack, M Bernstein, G Jovic, MD Krailo, ... The Lancet Oncology 17 (10), 1396-1408, 2016 | 494 | 2016 |
| Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort S Smeland, SS Bielack, J Whelan, M Bernstein, P Hogendoorn, MD Krailo, ... European journal of cancer 109, 36-50, 2019 | 493 | 2019 |
| Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of … CL Vale, S Burdett, LHM Rydzewska, L Albiges, NW Clarke, D Fisher, ... The lancet oncology 17 (2), 243-256, 2016 | 486 | 2016 |
| Perioperative β-blockade (Pobble) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial JT Powell, POBBLE Trial Investigators Journal of Vascular Surgery 41 (4), 602-609, 2005 | 457 | 2005 |
| Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma … IJ Lewis, MA Nooij, J Whelan, MR Sydes, R Grimer, PCW Hogendoorn, ... Journal of the National Cancer Institute 99 (2), 112-128, 2007 | 439 | 2007 |
| An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study GM Mead, MR Sydes, J Walewski, A Grigg, CS Hatton, P Norbert, ... Annals of Oncology 13 (8), 1264-1274, 2002 | 407 | 2002 |
| Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer W Xie, MM Regan, M Buyse, S Halabi, PW Kantoff, O Sartor, H Soule, ... Journal of Clinical Oncology 35 (27), 3097-3104, 2017 | 406 | 2017 |
Nicholas JamesProfessor of Prostate and Bladder Cancer Research, Institute of Cancer Research在 icr.ac.uk 的电子邮件经过验证
